Patents Assigned to E. R. Squibb and Sons, Inc.
  • Patent number: 5232453
    Abstract: A catheter holder has a pad of medical grade adhesive material having one surface for attachment to the skin of a wearer, and a pair of tapes secured to and extending from the other surface of the pad. A multiple use adhesive is placed on a surface of at least one tape which surface faces generally towards the other tape. With such an arrangement, the two tapes can be stuck together to enclose the catheter and at the same time the tape carrying the adhesive sticks to the adjacent wall of the catheter so preventing logitudinal movement of the catheter relative to the pad.
    Type: Grant
    Filed: June 17, 1992
    Date of Patent: August 3, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Ronald A. Plass, Keith G. M. Hollands
  • Patent number: 5233086
    Abstract: Racemic Feist's acid is treated with (R)-(+)-.alpha.-methylbenzylamine to yield (1R-trans)-3-methylene-cyclopropane-1,2-dicarboxylic acid, (R)-.alpha.-methylbenzylamine (1:1) salt. This salt can then be converted to (1R-trans)-3-methylene-1,2-cyclopropanedicarboxylic acid, dimethyl ester which is an intermediate in the preparation of the antiviral agent [1R-(1.alpha.,2.beta.,3.alpha.)]-2-amino-9-[2,3-bis(hydroxymethyl)cyclobut yl]-1,9-dihydro-6H-purin-6-one. The improved process also enables the recovery of racemic Feist's acid from the resolution.
    Type: Grant
    Filed: October 16, 1992
    Date of Patent: August 3, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Jollie D. Godfrey, Jr., Richard H. Mueller, Thomas P. Kissick, Janak Singh
  • Patent number: 5233076
    Abstract: A novel process and intermediates are disclosed for the preparation of the optically active compound ##STR1## wherein R.sup.3 is a protecting group. This cyclobutanone compound is used to prepare a compound of the formula ##STR2## having anti-viral activity.
    Type: Grant
    Filed: April 29, 1991
    Date of Patent: August 3, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventor: Saleem Ahmad
  • Patent number: 5226564
    Abstract: A synthetic plastic bag for containing liquids, e.g., urine, has a plastic outlet tube. It is manufactured by a first step of seam welding the tube between two superposed bag walls. In a subsequent step, an encircling sleeve is slide over the tube to a position where it contains within it the portions of the bag walls on either side of the tube. Thirdly, this sleeve is compressed onto the tube by a crimping operation conducted with the crimping force applied in a direction radially of the tube but at substantially right angles to the plane in which the bag walls lie. Alternatively, after the tube is seam welded between the bag walls, the bag and tube combination is then placed between the blocks of a mold, each block having confronting recesses of a particular shape and molten plastics material is injected to fill these recesses. The injected material forms a collar which completely surrounds the tube.
    Type: Grant
    Filed: January 4, 1991
    Date of Patent: July 13, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Peter L. Steer, Graham E. Steer
  • Patent number: 5225202
    Abstract: An enteric coated pharmaceutical composition is provided which includes a medicament which is sensitive to a low pH environment of less than 3, such as pravastatin, which composition is preferably in the form of pellets which includes an enteric coating formed of neutralized hydroxypropylmethyl cellulose phthalate, plasticizer and anti-adherent. The so-coated pellets have good resistance to deterioration at pH less than 3 but have good drug release properties at greater than 3.
    Type: Grant
    Filed: September 30, 1991
    Date of Patent: July 6, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Garry R. Hodges, David L. McCann
  • Patent number: 5225401
    Abstract: Congestive heart failure is treated by administration of a selective inhibitor of neutral endopeptidase and an angiotensin converting enzyme inhibitor. Captopril, fosinopril sodium, enalapril maleate and lisinopril are the preferred angiotensin converting enzyme inhibitors and the mercapto compounds of the formula ##STR1## are the preferred selective inhibitors of neutral endopeptidase.
    Type: Grant
    Filed: August 12, 1991
    Date of Patent: July 6, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventor: Andrea A. Seymour
  • Patent number: 5224935
    Abstract: A catheter retainer is disclosed that includes an adhesive pad with projections. The catheter is secured to the pad by being tied to the projections.
    Type: Grant
    Filed: November 12, 1992
    Date of Patent: July 6, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventor: Keith G. M. Hollands
  • Patent number: 5225408
    Abstract: Angiotension II inhibition is exhibited by ##STR1## wherein: R.sup.1 and R.sup.2 are each independently hydrogen, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, thiophenalkyl, pyridylalkyl, or --R.sup.8 CO.sub.2 R.sup.9 ;R.sup.3 is a single bond, --S--, or --O--;R.sup.4 is hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, aralkyl, cycloalkylalkyl, or thiophenalkyl;R.sup.7 --(CH.sub.2).sub.n --CO.sub.2 R.sup.9, ##STR2## --NHSO.sub.2 CF.sub.3, --SO.sub.3 H, --C(CF.sub.3).sub.2 OH, ##STR3## --PO.sub.3 H, ##STR4## --CONHOR.sup.12, --CONHNHSO.sub.2 CF.sub.3, --(CH.sub.2).sub.n --5--tetrazolyl (optionally substituted with R.sup.9), and the remaining symbols are as defined in the specification.
    Type: Grant
    Filed: December 20, 1991
    Date of Patent: July 6, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventor: Harold N. Weller, III
  • Patent number: 5223516
    Abstract: Compounds of the formula ##STR1## wherein Y can be tetrazolyl are disclosed. These compounds are useful as cardiovascular agents.
    Type: Grant
    Filed: April 24, 1991
    Date of Patent: June 29, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Norma G. Delaney, George C. Rovnyak, Melanie J. Loots
  • Patent number: 5217958
    Abstract: Compounds of the formula ##STR1## are disclosed. These compounds are inhibitors of renin and therefore useful as cardiovascular agents.
    Type: Grant
    Filed: April 12, 1990
    Date of Patent: June 8, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventor: Dinesh V. Patel
  • Patent number: 5218142
    Abstract: Racemic Feist's acid is treated with (R)-(+)-.alpha.-methylbenzylamine to yield (1R-trans)-3-methylenecyclopropane-1,2-dicarboxylic acid, (R)-.alpha.-methylbenzylamine (1:1) salt. This salt can then be converted to (1R-trans)-3-methylene-1,2-cyclopropanedicarboxylic acid, dimethyl ester which is an intermediate in the preparation of the antiviral agent [1R-(1.alpha.,2.beta.,3.alpha.)]-2-amino-9-[2,3-bis(hydroxymethyl)cyclobut yl]-1,9-dihydro-6H-purin-6-one. The improved process also enables the recovery of racemic Feist's acid from the resolution.
    Type: Grant
    Filed: October 16, 1992
    Date of Patent: June 8, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Jollie D. Godfrey, Jr., Richard H. Mueller, Thomas P. Kissick, Janak Singh
  • Patent number: 5215985
    Abstract: A method is provided for treatment of neuronal insult, such as caused by lack of oxygen, by administering an ATP-sensitive potassium channel blocker, such as a sulfonyl urea, for example, tolbutamide.
    Type: Grant
    Filed: January 27, 1992
    Date of Patent: June 1, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Kerry P. S. J. Murphy, Susan A. Greenfield
  • Patent number: 5212164
    Abstract: Compounds which are inhibitors of cholesterol biosynthesis (by inhibiting de novo squalene biosynthesis), and thus are useful as hypocholesterolemic agents and antiatherosclerotic agents are provided which have the structure ##STR1## wherein m is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4;Y.sup.1 and Y.sup.2 are H or halogen;R.sup.2, R.sup.3 and R.sup.4 may be the same or different and are independently H, metal ion, C.sub.1 to C.sub.8 alkyl or C.sub.3 to C.sub.12 alkenyl;X is O, S, NH or NCH.sub.2 R.sup.15 wherein R.sup.15 is H or C.sub.1 to C.sub.5 alkyl; andR.sup.1 is R.sup.5 --Q.sup.1 --Q.sup.2 --Q.sup.3 -- wherein R.sup.5, Q.sup.1, Q.sup.2 and Q.sup.3 are as defined herein;and when m is o, X is other than S; and if m is o and X is 0, then n is 1, 2, 3 or 4; including all stereoisomers thereof.
    Type: Grant
    Filed: March 29, 1990
    Date of Patent: May 18, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Scott A. Biller, Michael J. Sofia
  • Patent number: 5212165
    Abstract: A method is provided for rehabilitating or restoring the vasorelaxant action of the endothelium impaired by atherosclerosis and/or hypercholesterolemia, thereby preventing arteriospasm in the coronary arteries using an angiotensin converting enzyme inhibitor such as captopril, fosinopril, ceranapril, enalapril or lisinopril, which may be administered by oral or parenteral dosage forms.
    Type: Grant
    Filed: October 23, 1989
    Date of Patent: May 18, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: A. K. Gunnar Aberg, Miguel A. Ondetti
  • Patent number: 5212177
    Abstract: Novel compounds having the formula ##STR1## and its isomer ##STR2## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and X are as defined herein. These compounds inhibit the action of angiotensin II and are useful, therefore, for example, an antihypertensive agents.
    Type: Grant
    Filed: December 16, 1991
    Date of Patent: May 18, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Michael A. Poss, Karnail S. Atwal
  • Patent number: 5210262
    Abstract: A method is provided for preparing a phosphonic acid ester having the structure ##STR1## wherein R.sup.1 is farnesyl or a derivative or analog thereof, and R.sup.2 is lower alkyl, by treating a farnesyl halide R.sup.1 Hal(Hal=Cl,Br,I) with an alkoxide of the structure ##STR2## wherein M is an alkali metal and R.sup.2c is lower alkyl. The resulting phosphonic acid ester is an intermediate in preparing a squalene synthetase inhibitor which is used for inhibiting cholesterol biosynthesis.
    Type: Grant
    Filed: September 14, 1992
    Date of Patent: May 11, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Janak Singh, Richard H. Mueller
  • Patent number: 5208235
    Abstract: Novel compounds having the formula ##STR1## where X R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are as defined herein. These compounds inhibit the action of angiotensin II and are useful, therefore for example, as antihypertensive agents.
    Type: Grant
    Filed: March 10, 1992
    Date of Patent: May 4, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventor: Michael A. Poss
  • Patent number: 5208234
    Abstract: Novel compounds having the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined herein. These compounds inhibit the action of angiotensin II and are useful, therefore, for example, as antihypertensive agents.
    Type: Grant
    Filed: March 10, 1992
    Date of Patent: May 4, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventor: Michael A. Poss
  • Patent number: 5206244
    Abstract: Antiviral activity is exhibited by compounds having the formula ##STR1## and its pharmaceutically acceptable salts.
    Type: Grant
    Filed: September 20, 1991
    Date of Patent: April 27, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Robert Zahler, William A. Slusarchyk
  • Patent number: 5202486
    Abstract: Tetrahydronaphthaleneamine derivatives having the formula ##STR1## wherein R, R', R.sub.1 and R.sub.2 are as defined herein, are novel calcium channel blockers.
    Type: Grant
    Filed: July 31, 1990
    Date of Patent: April 13, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Joel C. Barrish, Steven H. Spergel